JP2007532594A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007532594A5 JP2007532594A5 JP2007507707A JP2007507707A JP2007532594A5 JP 2007532594 A5 JP2007532594 A5 JP 2007532594A5 JP 2007507707 A JP2007507707 A JP 2007507707A JP 2007507707 A JP2007507707 A JP 2007507707A JP 2007532594 A5 JP2007532594 A5 JP 2007532594A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- phenyl
- groups
- atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 Alkyne compounds Chemical class 0.000 claims 43
- 125000004432 carbon atom Chemical group C* 0.000 claims 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 15
- 229910052794 bromium Inorganic materials 0.000 claims 13
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 12
- PIGFYZPCRLYGLF-UHFFFAOYSA-N Aluminum nitride Chemical compound [Al]#N PIGFYZPCRLYGLF-UHFFFAOYSA-N 0.000 claims 11
- 125000004076 pyridyl group Chemical group 0.000 claims 10
- 229910052801 chlorine Inorganic materials 0.000 claims 9
- 239000000460 chlorine Substances 0.000 claims 9
- 125000004122 cyclic group Chemical group 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 8
- 239000013543 active substance Substances 0.000 claims 8
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 8
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 7
- 229910052740 iodine Inorganic materials 0.000 claims 7
- KZOWNALBTMILAP-JBMRGDGGSA-N ancitabine hydrochloride Chemical compound Cl.N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 KZOWNALBTMILAP-JBMRGDGGSA-N 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 4
- 229910021595 Copper(I) iodide Inorganic materials 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000002837 carbocyclic group Chemical group 0.000 claims 4
- 239000003054 catalyst Substances 0.000 claims 4
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 239000012467 final product Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 4
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 4
- 239000011630 iodine Substances 0.000 claims 4
- 229910052763 palladium Inorganic materials 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 150000004820 halides Chemical class 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 1
- 125000006698 (C1-C3) dialkylamino group Chemical group 0.000 claims 1
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 claims 1
- 125000004760 (C1-C4) alkylsulfonylamino group Chemical group 0.000 claims 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 206010002650 Anorexia nervosa and bulimia Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000032841 Bulimia Diseases 0.000 claims 1
- 125000003830 C1- C4 alkylcarbonylamino group Chemical group 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108010047068 Melanin-concentrating hormone receptor Proteins 0.000 claims 1
- 150000001345 alkine derivatives Chemical class 0.000 claims 1
- 125000006598 aminocarbonylamino group Chemical group 0.000 claims 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 235000005911 diet Nutrition 0.000 claims 1
- 235000021061 dietary behavior Nutrition 0.000 claims 1
- 230000000378 dietary effect Effects 0.000 claims 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000005045 dihydroisoquinolinyl group Chemical group C1(NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 235000006694 eating habits Nutrition 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 150000002366 halogen compounds Chemical class 0.000 claims 1
- 230000002140 halogenating effect Effects 0.000 claims 1
- 150000002466 imines Chemical group 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 102000006953 melanin-concentrating hormone receptor activity proteins Human genes 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004017932A DE102004017932A1 (de) | 2004-04-14 | 2004-04-14 | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| PCT/EP2005/003684 WO2005103029A1 (de) | 2004-04-14 | 2005-04-08 | Neue alkin-verbindungen mit mch-antagonistischer wirkung und diese verbindungen enthaltende arzneimittel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007532594A JP2007532594A (ja) | 2007-11-15 |
| JP2007532594A5 true JP2007532594A5 (enExample) | 2008-05-29 |
Family
ID=34966977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007507707A Pending JP2007532594A (ja) | 2004-04-14 | 2005-04-08 | Ｍｃｈ拮抗作用を有する新規アルキン化合物及び前記化合物を含む医薬 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1737839A1 (enExample) |
| JP (1) | JP2007532594A (enExample) |
| CA (1) | CA2559237A1 (enExample) |
| DE (1) | DE102004017932A1 (enExample) |
| WO (1) | WO2005103029A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7452911B2 (en) | 2002-10-31 | 2008-11-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
| DE10323345A1 (de) | 2003-05-23 | 2004-12-16 | Zentaris Gmbh | Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren |
| US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
| EP1790342A1 (de) | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege |
| CA2657183A1 (en) | 2006-08-25 | 2008-02-28 | Boehringer Ingelheim International Gmbh | New pyridone derivatives with mch antagonistic activity and medicaments comprising these compounds |
| TW200831485A (en) * | 2006-12-11 | 2008-08-01 | Boehringer Ingelheim Int | New pyridazine derivatives with MCH antagonistic activity and medicaments comprising these compounds |
| JP5514716B2 (ja) * | 2007-05-11 | 2014-06-04 | コリア・リサーチ・インスティテュート・オブ・ケミカル・テクノロジー | アリールピペリジン置換基を有するイミダゾール誘導体、その製造方法及びこれを含む医薬組成物 |
| WO2010050445A1 (ja) | 2008-10-27 | 2010-05-06 | 武田薬品工業株式会社 | 二環性化合物 |
| HUE041294T2 (hu) * | 2011-12-16 | 2019-05-28 | Poseida Therapeutics Inc | TRPC4 modulátorok a fájdalom kezelésére vagy megelõzésére |
| AU2018351059B2 (en) | 2017-10-19 | 2022-05-12 | Teijin Pharma Limited | Benzimidazole derivatives and their uses |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002003370A (ja) * | 1999-09-20 | 2002-01-09 | Takeda Chem Ind Ltd | メラニン凝集ホルモン拮抗剤 |
| CA2386474A1 (en) * | 1999-09-20 | 2001-03-29 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
| JP2002241274A (ja) * | 2000-04-28 | 2002-08-28 | Takeda Chem Ind Ltd | メラニン凝集ホルモン拮抗剤 |
| DE10139416A1 (de) * | 2001-08-17 | 2003-03-06 | Aventis Pharma Gmbh | Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| JP2005519876A (ja) * | 2001-11-27 | 2005-07-07 | メルク エンド カムパニー インコーポレーテッド | ２−アミノキノリン化合物 |
| WO2003097047A1 (en) * | 2002-05-13 | 2003-11-27 | Eli Lilly And Company | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes |
| JP4487774B2 (ja) * | 2002-09-30 | 2010-06-23 | 萬有製薬株式会社 | ２−アミノベンズイミダゾール誘導体 |
| DE10250708A1 (de) * | 2002-10-31 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| JP4630555B2 (ja) * | 2003-02-12 | 2011-02-09 | 武田薬品工業株式会社 | アミン誘導体 |
-
2004
- 2004-04-14 DE DE102004017932A patent/DE102004017932A1/de not_active Withdrawn
-
2005
- 2005-04-08 EP EP05739806A patent/EP1737839A1/de not_active Withdrawn
- 2005-04-08 WO PCT/EP2005/003684 patent/WO2005103029A1/de not_active Ceased
- 2005-04-08 JP JP2007507707A patent/JP2007532594A/ja active Pending
- 2005-04-08 CA CA002559237A patent/CA2559237A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007532596A5 (enExample) | ||
| ES2211624T3 (es) | Derivados de piperazina como antagonistas de 5-ht1b. | |
| FI101624B (fi) | Menetelmä terapeuttisesti käyttökelpoisten N-(3-hydroksi-4-piperidinyy li)(dihydrobentsofuraani-, dihydro-2H-bentsopyraani- tai dihydrobentso dioksiini)karboksamidijohdannaisten valmistamiseksi ja välituote | |
| CN100415716C (zh) | 1－(1，2－双取代哌啶基)－4－取代哌嗪衍生物 | |
| CN1134431C (zh) | 作为多巴胺d4受体拮抗剂的2,4-二氨基嘧啶衍生物 | |
| JP2010512366A5 (enExample) | ||
| RU2008120619A (ru) | (гетеро)арилы, обладающие антагонистической активностью по отношению к меланинконцентрирующему гормону | |
| US6319920B1 (en) | 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives | |
| JPH11147872A (ja) | Ｃｃｒ−３受容体アンタゴニスト | |
| WO2009022730A1 (ja) | Ｐ２ｘ４受容体拮抗剤 | |
| JP2005516006A5 (enExample) | ||
| JP2007532594A5 (enExample) | ||
| CA2420177C (en) | Quinazoline derivatives as alpha-1 adrenergic antagonists | |
| CN1938291A (zh) | 被取代的4－烷基－和4－烷酰基－哌啶衍生物和其作为神经激肽拮抗剂的用途 | |
| JP2005518368A (ja) | ムスカリン受容体アンタゴニストとしてのアミノテトラリン誘導体 | |
| JP2007520466A5 (enExample) | ||
| JP2007532593A5 (enExample) | ||
| JP2007532599A5 (enExample) | ||
| JP2006503056A (ja) | ヒスタミンｈ３受容体アンタゴニスト、その製造および治療用使用 | |
| CA2559237A1 (en) | Novel alkyne compounds having an mch-antagonistic effect and medicaments containing said compounds | |
| JP2007528884A5 (enExample) | ||
| JP2007527424A5 (enExample) | ||
| JP2009526844A (ja) | ピペラジン誘導体 | |
| CA2509088C (en) | Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists | |
| US7524862B2 (en) | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |